Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

DI MARCO, Vito
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.000
EU - Europa 11.047
AS - Asia 9.853
SA - Sud America 1.362
AF - Africa 268
OC - Oceania 37
Continente sconosciuto - Info sul continente non disponibili 15
Totale 45.582
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.714
SG - Singapore 3.856
RU - Federazione Russa 3.026
CN - Cina 2.410
IT - Italia 2.185
FI - Finlandia 1.390
BR - Brasile 1.083
HK - Hong Kong 990
VN - Vietnam 897
DE - Germania 875
UA - Ucraina 794
PL - Polonia 611
GB - Regno Unito 496
FR - Francia 452
IE - Irlanda 443
JP - Giappone 332
IN - India 261
BD - Bangladesh 225
SE - Svezia 217
KR - Corea 186
CA - Canada 129
TR - Turchia 123
IQ - Iraq 104
RO - Romania 99
AR - Argentina 95
MX - Messico 89
NL - Olanda 87
BE - Belgio 79
AT - Austria 76
ZA - Sudafrica 59
UZ - Uzbekistan 57
CI - Costa d'Avorio 48
ES - Italia 48
IR - Iran 44
PK - Pakistan 44
CO - Colombia 40
SA - Arabia Saudita 39
CZ - Repubblica Ceca 37
ID - Indonesia 36
EC - Ecuador 34
KE - Kenya 33
AU - Australia 31
MA - Marocco 31
PH - Filippine 31
VE - Venezuela 30
GR - Grecia 26
NP - Nepal 26
EG - Egitto 25
JO - Giordania 25
MY - Malesia 25
PY - Paraguay 25
AE - Emirati Arabi Uniti 20
CL - Cile 19
TN - Tunisia 18
LT - Lituania 17
AZ - Azerbaigian 16
CH - Svizzera 16
DZ - Algeria 15
TH - Thailandia 15
LB - Libano 14
BO - Bolivia 12
BG - Bulgaria 11
KG - Kirghizistan 11
UY - Uruguay 11
DK - Danimarca 10
HN - Honduras 10
OM - Oman 10
DO - Repubblica Dominicana 9
PA - Panama 9
AL - Albania 8
BY - Bielorussia 8
EU - Europa 8
GE - Georgia 8
IL - Israele 8
MM - Myanmar 8
PE - Perù 8
CR - Costa Rica 7
ET - Etiopia 7
GT - Guatemala 7
JM - Giamaica 7
KZ - Kazakistan 7
RS - Serbia 7
MD - Moldavia 6
NG - Nigeria 6
NI - Nicaragua 6
SN - Senegal 6
GA - Gabon 5
GY - Guiana 5
PT - Portogallo 5
TW - Taiwan 5
XK - ???statistics.table.value.countryCode.XK??? 5
BA - Bosnia-Erzegovina 4
BN - Brunei Darussalam 4
PS - Palestinian Territory 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
CU - Cuba 3
FJ - Figi 3
NZ - Nuova Zelanda 3
SV - El Salvador 3
Totale 45.540
Salva come PNG Salva come JPEG
Città #
Fairfield 2.834
Ashburn 2.814
Singapore 2.722
Woodbridge 1.437
Chandler 1.311
Houston 1.160
Wilmington 1.139
Seattle 1.089
San Jose 1.076
Cambridge 993
Hong Kong 943
Ann Arbor 867
Palermo 555
Zgierz 523
Moscow 502
Dublin 439
Jacksonville 415
Medford 397
Beijing 394
Los Angeles 379
Des Moines 348
Ho Chi Minh City 320
Tokyo 315
Santa Clara 304
New York 303
Helsinki 292
Altamura 284
Council Bluffs 275
Nanjing 268
Frankfurt am Main 261
Princeton 252
Lauterbourg 239
Hanoi 235
Lawrence 212
Chicago 190
San Diego 183
Dallas 169
Boardman 157
Hefei 143
The Dalles 134
Buffalo 131
Tulsa 109
Shenyang 99
São Paulo 98
Milan 94
Dearborn 82
Jinan 75
London 74
Brussels 72
Orem 72
Phoenix 71
Nanchang 70
Tianjin 69
Changsha 67
Nuremberg 66
Rome 66
Warsaw 63
Jiaxing 60
Ludwigshafen am Rhein 60
Hebei 59
Izmir 59
Columbus 53
Chennai 50
Salt Lake City 50
Zhengzhou 50
Abidjan 48
Atlanta 47
Falls Church 45
Guangzhou 43
Tashkent 43
Saint Petersburg 41
Baghdad 40
Kumar 40
Tampa 40
Haiphong 39
San Paolo di Civitate 39
Da Nang 38
Amsterdam 37
Ningbo 36
Seongnam 36
Elk Grove Village 35
Denver 34
Munich 34
Brooklyn 33
Stockholm 33
Johannesburg 32
Mumbai 31
Nairobi 31
Montreal 30
Verona 30
Ottawa 29
Rio de Janeiro 29
Hangzhou 28
Seoul 28
Shanghai 27
Redwood City 26
Vienna 26
Bremen 24
Brno 24
Manchester 24
Totale 29.892
Salva come PNG Salva come JPEG
Nome #
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases 514
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 387
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 333
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b 326
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 324
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 306
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 301
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease 298
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 296
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 295
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 292
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin 287
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 284
Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. 280
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 278
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 273
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 271
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 269
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 269
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated amplification assay 263
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 262
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 258
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 253
Targeted Therapies in Hepatocellular Carcinoma 252
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 251
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 248
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 246
Breaking bad news: How to cope 246
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 245
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 244
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 244
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 244
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 242
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 239
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 238
Adefovir for lamivudine resistant HBV: More than meets the eye. 235
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 235
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 233
La termoablazione nel trattamento delle neoplasie epatiche primitive e secondarie 231
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 230
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 229
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 229
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 227
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 226
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 226
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 226
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 226
Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy. 224
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 224
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 222
A patient with acute hepatitis C and possible IFN toxicity [2] 222
Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease 220
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 218
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 218
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 217
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 216
STAGING OF FIBROSIS BY LIVER STIFFNESS MEASUREMENT IN THALASSEMICS WITH IRON OVERLOAD 215
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. 214
Halitosis: could it be more than mere bad breath? 214
Oral Mucosa of celiac disease patients produces anti-endomysial and anti-transglutaminase antibodes. Diagnostic usefulness of an in vitro culture system 213
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 213
Liver disease in chelated transfusion-dependent thalassemics: the role of iron and chronic hepatitis C 212
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. 211
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 211
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 209
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 209
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 209
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 208
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients 208
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. 207
Serum BLYS/BAFF levels in acute hepatitis C predict clinical outcome 204
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 204
HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy 199
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study 199
Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. 198
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 196
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study 195
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy 195
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 195
HCV clearance among hemophiliacs and beta-thalassemics 194
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C 194
AISF position paper on HCV in immunocompromised patients 194
Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials 193
Sorafenib: from literature to clinical practice 193
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 193
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 193
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. 191
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 191
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 190
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C 190
Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with Nonalcoholic fatty liver disease 190
Hepatic expression of cyclooxygenase-2 in non alcoholic fatty liver disease 189
Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. 189
Metformina e pioglitazone in soggetti affetti da diabete mellito tipo 2 con steatosi epatica 188
CLINICAL COURSE OF NIMESULIDE-INDUCED LIVER INJURY 188
Serum γ-glutamyl transferase levels, insulin resistance and liver fibrosis in patients with chronic liver diseases. 188
Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction 188
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. 188
Liver stiffness quantification in patients with non-alcoholic steatohepatitis: comparison of shear wave elastography and transient elastography with liver biopsy correlation 188
Mortality in patients with hepatocellular carcinoma predicted by six scoring: none is the winner 187
Totale 23.329
Salva come PNG Salva come JPEG
Categoria #
all - tutte 160.799
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.799
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021701 0 0 0 0 0 0 0 0 0 0 339 362
2021/20223.080 137 659 128 94 107 134 172 165 379 371 224 510
2022/20233.944 390 835 51 419 413 625 274 264 426 17 155 75
2023/20241.552 76 244 106 116 132 388 144 85 22 37 12 190
2024/20254.837 106 290 217 424 155 185 297 258 369 898 604 1.034
2025/202617.023 1.145 490 909 1.369 1.710 2.773 2.329 1.901 1.373 2.282 742 0
Totale 46.774